Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement
نویسندگان
چکیده
منابع مشابه
Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement
BACKGROUND Personalized medicine is gradually emerging as a transformative field. Thus far, seven co-developed drug-diagnostic combinations have been approved and several dozen post-hoc drug-diagnostic combinations (diagnostic approved after the drug). However, barriers remain, particularly with respect to reimbursement. Purpose, methods: This study analyzes barriers facing uptake of drug-diagn...
متن کاملMedicines Compliance and Reimbursement Level in Portugal
During a severe financial crisis, it is a priority to use scientific evidence to identify factors that enable therapeutic compliance by patients. This study aimed to evaluate a possible association between the number of patients who attended a medical appointment and had medicine prescribed and the number of these same patients who purchased the prescribed medicine and whether the level of reim...
متن کاملAssessing Personalized Medicines in Australia
BACKGROUND Since the mapping of the human genome in 2003, the development of biomarker targeted therapy and clinical adoption of "personalized medicine" has accelerated. Models for insurance subsidy of biomarker/test/drug packages ("codependent technologies" or technologies that work better together) are not well developed. Our aim was to create a framework to assess the safety, effectiveness, ...
متن کاملRegistration and Reimbursement of New Cancer Medicines in Australia.
I read with interest the article by Macaulay et al. [1] in a recent issue of Value in Health Regional Issues for Asia on the registration and reimbursement of certain medicines for patients with cancer in Australia. This topic is of considerable public interest in Australia given the current Senate inquiry on timely access to new medicines for patients with cancer on the Pharmaceutical Benefits...
متن کاملMedicines and the media: news reports of medicines recommended for government reimbursement in Australia
BACKGROUND Previous analyses of the listings of trastuzumab on the Australian Pharmaceutical Benefits Scheme (PBS) and HPV vaccine on the National Immunisation Program (NIP) suggest a media influence on policy makers. We examined the timing and content of Australian newspaper reports of medicines in relation to Pharmaceutical Benefits Advisory Committee (PBAC) decisions. METHODS We identified...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Personalized Medicine
سال: 2014
ISSN: 2075-4426
DOI: 10.3390/jpm4020163